

# Global burden of hepatitis & use of pooled procurement to expand access

H. Razavi (homie.razavi@centerforda.com)

http://www.thecdafoundation.org

The goal of the CDA Foundation is to provide support countries to achieve hepatitis elimination targets






http://polarisobservatory.org

http://gprofund.org

 Mission Statement: Provide data, tools, training and decision analytics to support elimination of hepatitis B and C globally by 2030 Mission Statement: Provide access to low cost, quality medicines and diagnostics through pooled procurement


### The Polaris Observatory provides a range of free services to countries




# A Delphi process is used to develop consensus estimates for each country

ID Experts	Literature Search	Meeting 1 – Review Inputs	Analysis/ Modeling	Meeting 2 – Develop Strategies	Final Report/ Follow up	
MoH Representatives Public Health Specialists Epidemiologists Hepatologists, Gastro. ID Specialists Economists	Indexed Journals, Gov Reports International Reports Cancer Registries Liver Transplant Registries Risk Group Reports	Review Inputs ID Data Gaps ID Data Sources/ Unpublished Data Discuss Analogues Discuss Risk Factors Discuss Age Distribution Discuss Regional Variations	Gather Unpublished Data Analyze Data Populate & Calibrate Model Generate Analyses	Review Inputs & Build Consensus Review Outputs & Build Consensus Assess Potential Scenarios Agree on Final Desired Strategies	Refine Analysis Draft Report Draft Manuscript Draft/ Submit Abstracts	

## An estimated 69.6 (61.4 – 78.1) million individuals were HCV+ with an overall prevalence of 1.0% (0.8%- 1.1%) in 2016



#### **Global HCV Cascade of Care in 2016**




Source: Polaris Observatory (http://www.polarisobservatory.org/)

### Significant increases in screening and treatment are required to achieve global WHO elimination targets for HCV


- Newly diagnosed will need to increase to 4.5 million annually
- The diagnosed population needs to be linked to care
- The annual number of treated patients needs to increase to 5.1 million
- · This will require expanding treatment beyond specialists
- Increase in harm reduction is required to reduce new infections
- All restrictions need to be removed to treat younger/early stage patients

	2016	2018	2019	2020	2021	2024
Newly Diagnosed	1,400,000	3,740,000	4,500,000	4,500,000	4,500,000	4,500,000
Treated	1,600,000	1,750,000	2,000,000	2,000,000	5,000,000	5,100,000
Fibrosis Stage	>= F1	>= F0				
Treated Age	20-69	20-69	20-69	20-69	20-74	20-69
SVR	86%	90%	90%	90%	90%	90%

An estimated 278 million (244 million – 322 million) individuals were HBsAg+ with an overall prevalence of 3.7% (3.3 – 4.3%) in 2016



### An estimated 1.8 million (1.5 million – 2.1 million) five year olds were HBsAg+ with an overall prevalence of 1.3% (1.3% – 1.8%) in 2016




## In 2016, we brought together a group of stakeholders to develop a mechanism to expand access for low & middle income countries



- Donors/ Banks World Bank, Global Fund
- Country Representatives Viet Nam, Malaysia
- Global Health Organizations US CDC, CHAI, PharmAccess, Viral Hepatitis Prevention Board, Pharos, Wisper
- Civil Society World Hepatitis Alliance
- Originator Pharma AbbVie, Gilead, Merck
- Generic Pharma Ferozsons, Hetero, Mylan, Strides,
- Diagnostic Manufacturers Abbott, Cepheid, Roche

# The Global Procurement Fund pools orders from multiple countries to negotiate & place large orders



## The current GPRO negotiated prices are below what most countries can get on their own

Price per Unit	Units	
\$50.00	Bottle/pack of 28 tablets	
\$35.00	Bottle/pack of 28 tablets	
\$3.50	Bottle/pack of 30 tablets	
\$12.50	Bottle/pack of 30 tablets	
\$17.10	One test/cartridge	
	\$50.00 \$35.00 \$3.50 \$12.50	

These prices are available to 100+ low and middle income countries

#### **Conclusions**

- Total number of HCV infections is declining at more than 1 million individuals per year due to treatment and mortality
- The number of HCV patients being treated is dropping globally as the pool of patients, already under care, is being depleted
- Screening and linking diagnosed patients to care is key to HCV elimination
- We are completely baffled why HBV has not been eliminated already
- Pooled procurement does work it does lead to lower prices
- This does not mean that countries can not negotiate lower prices on their own
- Political will is needed to achieve hepatitis elimination